

1 **Adjusted booster schedules disperse age-dependent differences in antibody titers**
2 **benefitting risk populations**
3 **- Update to: Age-dependent Immune Response to the BioNTech/Pfizer BNT162b2**
4 **Coronavirus Disease 2019 Vaccination**

5 Lisa Müller^{1*±}, Marcel Andréé^{1*}, Wiebke Moskorz^{1*}, Ingo Drexler¹, Sandra Hauka¹, Johannes
6 Ptok¹, Lara Walotka¹, Ramona Grothmann¹, Jonas Hillebrandt^{1, 2}, Anastasia Ritchie¹, Laura
7 Peter¹, Andreas Walker¹, Jörg Timm¹, Ortwin Adams^{1#}, Heiner Schaal^{1#}

8

9 ¹ Institute of Virology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine
10 University Düsseldorf, Düsseldorf, Germany.

11 ² Department of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine
12 University Düsseldorf, Düsseldorf, Germany.

13

14 * contributed equally

15 # contributed equally

16 ± = corresponding author: Lisa.Mueller@uni-duesseldorf.de

17

18 **Abstract**

19 We provide follow-up data on the humoral immune response after COVID-19 vaccinations of
20 a cohort aged below 60 and over 80 years. While anti-SARS-CoV-2 spike-specific IgG and
21 neutralization capacity waned rapidly after initial vaccination, additional boosters highly
22 benefitted humoral immune responses including neutralization of Omikron variants in the
23 elderly cohort.

24

25 **Keywords**

26 SARS-CoV-2; COVID-19; neutralizing antibodies; vaccination; humoral immune response;
27 longitudinal study

28 **Introduction**

29 From the onset of the SARS-CoV-2 pandemic in 2019, it quickly became clear that only
30 prophylactic immunization offered a way out of this global health crisis [1, 2]. In the following
31 year 2020, several manufacturers received emergency use authorization for their vaccines
32 against SARS-CoV-2. This included the novel class of mRNA vaccines, Comirnaty
33 (BioNTech/Pfizer) and Spikevax/mRNA-1273 (Moderna) [3, 4].

34 In Germany and other countries, immunization schedules were rolled out at the end of
35 December 2020, prioritizing risk populations including immunocompromised and elderly
36 individuals [5]. With mRNA vaccines being the first of their kind, vaccinated risk populations
37 were in the focus of monitoring studies to evaluate the magnitude and quality of the immune
38 response to these vaccines [6, 7]. While initially, both mRNA formulations were designed as
39 "prime and boost" immunizations, several studies quickly pointed out the potential necessity
40 of at least a third vaccination, especially for populations with a generally reduced or short
41 lived humoral immune response [2, 8].

42 With the emergence of more variants of concern such the currently predominant Omikron
43 variants which again caused a sharp surge in cases worldwide, the necessity of adjusted
44 vaccination schedules became more evident. Therefore, less than a year after the first
45 vaccination campaigns started, several countries began their additional booster campaigns.
46 However, the combination of increasing case numbers and both, hetero- and homologous
47 booster vaccinations, predominantly using mRNA vaccines, has led to a complex mixture of
48 SARS-CoV-2-specific immunological profiles throughout the population.

49 Early in 2021, we performed a cohort study with two distinct age groups, vaccinees below 60
50 and above 80 years [9]. Here, we present a follow up of this vaccinee cohort. We revisited
51 the study cohort half a year and one year after their initial prime and boost vaccination. We
52 monitored the cohort for their total anti-SARS-CoV-2 spike-specific and nucleocapsid-specific
53 immune response as well as the magnitude of the neutralizing antibody response. Now that
54 Omikron is the most prevalent variant, we also included the neutralizing antibody response to
55 the Omikron BA.1 and BA.5. The follow-up of this cohort provides an important snapshot of
56 current immunological profiles.

57

58 **Results**

59 Participants were volunteers from the SBK nursing home in Cologne, Germany who
60 participated in both blood samplings for first part of the study (blood collection BC#1 and
61 BC#2, analyzed in Müller et. al., 2021 [9]) and in both follow-ups (blood collection BC#3 and
62 BC#4) and gave informed consent (n = 84). They received their 1st vaccination with the
63 BioNTech/Pfizer vaccine at the end of December 2020 and their 2nd in late January 2021. All
64 individuals received their 3rd vaccination (97.7% BioNTech, 2.3% Moderna) between
65 September and November 2021. Additionally, 39 (46.4 %) of the participants received a 4th
66 vaccination in early February 2022 (100% BioNTech), 8 of the younger vaccinees, 31 of the
67 elderly.

68 Blood samples were analyzed for anti-SARS-CoV-2 nucleocapsid-specific (Abbott) and
69 spike-specific (Euroimmun) IgG titers and neutralizing SARS-CoV-2 antibodies against B.1
70 WT (EPI_ISL_425126), Omikron BA.1 (EPI_ISL_12813299.1) and BA.5
71 (EPI_ISL_14167576) isolates about 6- and 12-months (BC#3 and BC#4) after their first
72 vaccination to screen for age-related differences in the longevity of the humoral immune
73 response and the induction of the antibody response post booster-vaccinations. Participants
74 who reported an infection six months prior to the second follow-up (n =20) were analyzed
75 separately. This resulted in a final cohort of 64 vaccinated individuals (28 younger, 36
76 elderly).

77 At the first follow-up blood collection (BC#3) six months after their first vaccination, the
78 quantitative SARS-CoV-2 spike-specific IgG titers again differed significantly between the
79 two groups ($p = 0.0435$). For the group of elderly vaccinees, the mean IgG titer was 99.98
80 BAU/mL, ranging from 3.45 to 1111.0 BAU/mL. In this group, 41.6% of the tested individuals
81 had titers below cut-off (>35.2 BAU/mL). In the younger cohort, IgG titers ranged from 84.3 to
82 823.5 BAU/ml with a mean of 231.6 BAU/ml with no participants testing below cut-off (Figure
83 1A). At the second follow-up (BC#4) more than one year after the initial vaccination
84 schedules, all participants had received a 3rd vaccination. Furthermore, 86% (n= 31) of the
85 elderly participants received a 4th vaccination, while only 28% (n = 8) of the younger
86 participants received the additional booster. At this blood collection (BC#4), SARS-CoV-2
87 spike-specific IgG titers were comparable between the age groups. Interestingly, the mean
88 SARS-CoV-2 spike-specific IgG titer in the group of elderly vaccinees was two-fold higher
89 (3337 BAU/mL) than for younger vaccinees (1663 BAU/mL) and no participant tested below
90 cut-off. However, titers ranged wider in the former group (68.0 – 10800 BAU/mL) than in the
91 latter (300 – 6950 BAU/mL).

92 Furthermore, we compared the time-dependent progress of the neutralization capacity
93 against a SARS-CoV-2 B.1 WT isolate between the age groups (Figure 1B). At the first

94 follow-up (BC#3), the median neutralization titer (MNT) in the group of elderly participants
95 drastically decreased to 0. After the elderly participants received their 3rd and 4th vaccination
96 (BC#4), however, the MNT for the group of elderly participants was 640. For the group of
97 younger vaccinees, MNT were significantly higher compared to the elderly. At the first follow-
98 up (BC#3), median neutralization capacity against the B.1 WT isolate in this group was
99 decreased to 20. At the one-year follow-up blood collection (BC#4), the MNT in the group of
100 younger vaccinees was 320.

101 The neutralization capacity determined by MNT was significantly decreased against both
102 Omikron variants (BA.1 and BA.5) in both groups as compared to the B.1 WT. The MNT
103 against Omikron BA.1 in the group of elderly participants was 160, against BA.5 it was
104 decreased to 20 compared to 640 against the WT. Younger vaccinees showed an MNT of 40
105 against BA.1 and 10 against BA.5 compared to 320 against the WT isolate (Figure 1C).

106 Furthermore, we separately analyzed the group of vaccinated convalescent participants (n =
107 20) compared to the overall vaccinated cohort (n = 64). The 20 convalescent participants (10
108 younger and 10 older vaccinees), reported an infection confirmed by PCR within the past six
109 months prior to the second follow-up blood collection, 9 were infected in a community
110 outbreak in early February 2022. A comparison of overall anti-SARS-CoV-2 spike-specific
111 IgG titers showed significantly higher titers ($p < 0.0001$) in the group of convalescent
112 participants with a mean titer of 8560 BAU/mL compared to 2605 BAU/mL in the vaccinated
113 cohort. It is of note that only 6 of 20 convalescent participants had anti-SARS-CoV-2
114 nucleocapsid-specific titers considered positive (Figure 1D).

115 In this cohort, we also analyzed neutralizing antibodies and compared the WT and Omikron
116 titers against the vaccinated cohort. In line with overall anti-SARS-CoV-2 spike-specific IgG
117 levels, the convalescent cohort displayed significantly higher neutralizing antibody levels
118 against WT and both Omikron isolates. However, despite the majority being infected with
119 Omikron during the community outbreak in February 2022, Omikron neutralization titers were
120 still lower than WT titers (Figure 1E).

121

122

123 **Discussion**

124 We present the follow-up analysis of the SARS-CoV-2-specific antibody response to the
125 BioNTech/Pfizer prime/boost vaccination of a cohort consisting of two age groups half a year
126 and one year after their first COVID-19-vaccination.

127 Both mRNA vaccinations that received emergency approval in late 2020 were initially
128 designed as “prime/boost” vaccination schedules, however, longitudinal effects of the
129 vaccinations were still to be determined. While it is evident that prophylactic immunizations
130 decreased the pandemic burden and positively influenced the development of hospitalization
131 and death rates [10], various studies pointed out potential limitations of the COVID-19-
132 vaccinations in specific sub-cohorts. These include immunocompromised patients, in
133 particular organ transplant recipients [11] as well as elderly where the reduced induction of
134 the humoral immune response after vaccination can likely be attributed to the effect of
135 immunosenescence.

136 In this follow-up study, we observed a drastic decrease of the anti-SARS-CoV-2 spike-
137 specific IgG titer at the first follow-up blood collection six months after the cohort received
138 their first vaccination. Especially in the group of elderly participants, these effects were even
139 more pronounced, with more than a third of the elderly vaccinees testing below cut-off. This
140 is in line with other studies which report a rapid antibody waning after prime/boost regimens
141 [12]. It further underlines the necessity of strategies to overcome such limitations with
142 additional boosters.

143 Thus, shortly after the first follow-up, study participants received an asynchronous 3rd mRNA
144 vaccination between September and November 2021, less than a year after their first
145 vaccination. In early February 2022, Germany's vaccination commission recommended
146 another booster for risk groups, so the majority of elderly participants received a 4th
147 vaccination before the second follow-up blood collection. This fully dispersed the age-
148 dependent difference in mean IgG titers and neutralization capacity, although, as previously
149 described, neutralization capacity against the Omikron BA.1 was drastically reduced, which
150 was even more pronounced for BA.5 [13]. As shown in large cohort studies with participants
151 aged over 60, the 4th vaccination resulted in elevated protection from severe illness,
152 hospitalization and death and even short-lived protection from infection and thus, proved
153 highly beneficial for risk groups [14, 15].

154 In the group of convalescent individuals, the humoral immune response was significantly
155 increased compared to the vaccinated cohort, which is in line with previous results [16].
156 While a high number of convalescents was infected during an Omikron BA.1 outbreak shortly
157 before the second follow-up blood collection, both Omikron neutralization titers were lower

158 than the neutralization titers against the B.1 WT, although neutralization titers against the WT
159 were also significantly increased, suggesting a simultaneous induction of cross-reactive
160 neutralizing antibodies against both variants [17]. Furthermore, anti-SARS-CoV-2
161 nucleocapsid-specific antibodies traditionally used as serological marker for natural infections
162 were only detected in the minority of convalescent individuals. With increasing break-through
163 infections in vaccinated individuals and data from large-scale cohort studies that showed the
164 rapid decline of nucleocapsid specific antibodies especially in vaccinees [18], it seems highly
165 likely that this serological marker will become even more unreliable with the rise of more
166 complex immunological profiles.

167

168

169 **Notes**

170 **Ethics Approval:** The ethics committee of the Medical Faculty at the Heinrich-Heine
171 University Düsseldorf, Germany (study no. 2021-1287), approved the study.

172 **Financial support.** This work was supported by Stiftung für Altersforschung, Düsseldorf [to
173 H.S., L.W.], Jürgen Manchot foundation [to H.S., I.D. L.M., L.W., A.R., J.T., R.G.], by
174 research funding from Deutsche Forschungsgemeinschaft (DFG, German Research
175 Foundation) grant GK1949/2 and project number 452147069 [to I.D.], by the Ministry of
176 Labour, Health and Social Affairs of North-Rhine Westphalia (CPS-1-1A), by the Federal
177 Ministry of Education and Research (01KX2021) and by the Forschungskommission of the
178 Medical Faculty, Heinrich-Heine-Universität Düsseldorf [to H.S., J.P., J.H.]

179 **Acknowledgments.** The authors thank the members of Sozial Betriebe Köln, SBK for
180 excellent organization and support and for the opportunity to conduct this study and all
181 helpers and the caregivers at SBK for their support at the blood collection days. We would
182 like to thank all volunteers at the SBK nursing home. We thank all members of the Virology
183 department and especially Yvonne Dickschen, Alexandra Graupner and Björn Wefers for
184 their excellent technical assistance.

185 **Potential conflicts of interest.** The authors: No reported conflicts of interest. All authors
186 have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

187 **Author contributions.** Conceptualization: HS, OA, MA, LM, Formal analysis: WM, LM,
188 Investigation: All Authors; Writing – original draft preparation: HS, WM, OA, MA, LM, Writing
189 – review and editing: All Authors, Supervision: HS, OA, MA, LM

190

191

192

193

194 **Figure 1: A** Anti-SARS-CoV-2 spike specific antibody titers were determined for both age
195 groups at each blood collection (BC#1 and BC#2 analyzed in Müller et. al., 2021 [9]).
196 Antibody titers below the detection limit were set to 1.0. Boxes span the interquartile range;
197 the line within each box denotes the median and whiskers indicate the 2.5 and 97.5
198 percentile values. **B** Neutralization titers of the two age groups were measured at each blood
199 collection. Individuals who received an additional booster vaccination before the fourth blood
200 collection are indicated with red symbols. **C** Comparison of the neutralization titers against a
201 B.1 WT strain and Omikron BA.1 and BA.5 isolates between the two age groups at the fourth
202 blood collection. **D** Comparison of anti-SARS-CoV-2 spike IgG titers between vaccinated
203 only and vaccinated convalescent individuals at the fourth blood collection. Convalescent
204 individuals with an anti-SARS-CoV-2 nucleocapsid-specific IgG titer considered positive are
205 marked in yellow. **E** Comparison of the neutralization titers against B.1 WT and BA.1 and
206 BA.5 Omikron isolates of the vaccinated only and vaccinated convalescent cohort. All data
207 sets were tested with the Shapiro-Wilk test for normality. As most data sets did not show
208 normal Gaussian distribution, parametric tests were performed. Two unpaired data sets (D)
209 were compared by two-tailed Mann Whitney test. Comparison of two paired data sets (C and
210 E) were done by two-tailed Wilcoxon matched-pairs signed rank test. For the comparison of
211 antibody titers at different time points (A and B), tests within age groups were tested with
212 two-tailed Friedman Test and comparison between age groups were tested with Kruskal
213 Wallis Test (between), both followed by Dunn's multiple comparison test. All tests were
214 performed using GraphPad Prism software Version 9.3.1.

215





216

217

218 References

- 219 1. Viana J, van Dorp CH, Nunes A, et al. Controlling the pandemic during the SARS-CoV-2
220 vaccination rollout. *Nat Commun* **2021**; 12(1): 3674.
- 221 2. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
222 Vaccination Setting. *N Engl J Med* **2021**; 384(15): 1412-23.
- 223 3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
224 Vaccine. *N Engl J Med* **2021**; 384(5): 403-16.
- 225 4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
226 Vaccine. *N Engl J Med* **2020**; 383(27): 2603-15.
- 227 5. Cylus J, Panteli D, van Ginneken E. Who should be vaccinated first? Comparing vaccine
228 prioritization strategies in Israel and European countries using the Covid-19 Health System
229 Response Monitor. *Isr J Health Policy Res* **2021**; 10(1): 16.
- 230 6. Oliveira-Silva J, Reis T, Lopes C, et al. Humoral response to the SARS-CoV-2 BNT162b2 mRNA
231 vaccine: Real-world data from a large cohort of healthcare workers. *Vaccine* **2022**; 40(4):
232 650-5.
- 233 7. Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of Messenger RNA Coronavirus Disease
234 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
235 CoV-2) Infection in a Cohort of Healthcare Personnel. *Clinical infectious diseases : an official
236 publication of the Infectious Diseases Society of America* **2021**; 73(6): e1376-e9.
- 237 8. Wieske L, van Dam KPJ, Steenhuis M, et al. Humoral responses after second and third SARS-
238 CoV-2 vaccination in patients with immune-mediated inflammatory disorders on
239 immunosuppressants: a cohort study. *Lancet Rheumatol* **2022**; 4(5): e338-e50.
- 240 9. Müller L, Andree M, Moskorz W, et al. Age-dependent Immune Response to the
241 Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. *Clinical infectious diseases
242 : an official publication of the Infectious Diseases Society of America* **2021**; 73(11): 2065-72.
- 243 10. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks
244 in the United States. *medRxiv* **2021**.
- 245 11. Lee A, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised
246 patients: systematic review and meta-analysis. *Bmj* **2022**; 376: e068632.
- 247 12. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of
248 BNT162b2 or ChAdOx1. *Lancet* **2021**; 398(10298): 385-7.
- 249 13. Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron
250 Subvariants BA.2.12.1, BA.4, and BA.5. *N Engl J Med* **2022**; 387(1): 86-8.
- 251 14. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2 against
252 Omicron in Israel. *N Engl J Med* **2022**; 386(18): 1712-20.
- 253 15. Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine
254 against hospitalization and death from COVID-19 in adults aged over 60 years. *Nature
255 medicine* **2022**; 28(7): 1486-90.
- 256 16. Muller L, Andree M, Ostermann PN, et al. SARS-CoV-2 Infection in Fully Vaccinated
257 Individuals of Old Age Strongly Boosts the Humoral Immune Response. *Front Med (Lausanne)*
258 **2021**; 8: 746644.
- 259 17. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters
260 induce neutralizing immunity against SARS-CoV-2 Omicron variant. *medRxiv* **2021**.
- 261 18. Krutikov M, Palmer T, Tut G, et al. Prevalence and duration of detectable SARS-CoV-2
262 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of
263 the pandemic (VIVALDI study): prospective cohort study in England. *Lancet Healthy Longev*
264 **2022**; 3(1): e13-e21.

265

A**B****C****D****E**